Antiviral effects of type I IFNs were not obvious, probably due to the fact that SARS-CoV infected cells inhibit STAT-1 signalling and viral replication peaks early after infection when treatment with pegylated IFN-α started. The gene discussed is IFNA1; the disease is infection.